Patterns of Recurrence on Cutaneous Melanoma: A Literature Review
暂无分享,去创建一个
C. Navarrete-Dechent | Francisca Donoso | Leonel Hidalgo | Dominga Peirano | Sebastián Vargas | Rosario Agüero | Pablo Uribe | Sebastían Mondaca
[1] A. Jemal,et al. Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.
[2] Shenmin Zhang,et al. Prediction of early-stage melanoma recurrence using clinical and histopathologic features , 2022, npj Precision Oncology.
[3] D. Coit,et al. Fifty years of progress in surgical oncology: Melanoma , 2022, Journal of surgical oncology.
[4] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. , 2022, European journal of cancer.
[5] A. Lallas,et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.
[6] N. Khushalani,et al. Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better? , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[7] J. Malvehy,et al. Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence , 2021, Acta dermato-venereologica.
[8] B. Oh,et al. Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. , 2020, Journal of the American Academy of Dermatology.
[9] P. Ascierto,et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. , 2020, The Lancet. Oncology.
[10] P. Spanheimer,et al. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma , 2020, The British journal of surgery.
[11] A. Masiak,et al. Long-term Follow-up , 2020, Definitions.
[12] M. Hendriks,et al. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] V. Sondak,et al. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival , 2019, Annals of Surgical Oncology.
[14] J. Larkin,et al. Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate‐risk cutaneous melanoma , 2019, The British journal of surgery.
[15] R. Zitsch,et al. Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients , 2019, Head & neck.
[16] J. Wayne,et al. Follow‐up of the melanoma patient , 2018, Journal of surgical oncology.
[17] Jeffrey E Gershenwald,et al. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[18] Nooreen Dabbish,et al. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. , 2017, Journal of the American College of Surgeons.
[19] D. Coit,et al. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients , 2017, Annals of Surgical Oncology.
[20] A. Barbour,et al. Primary cutaneous melanoma of the scalp: Patterns of recurrence , 2017, Journal of surgical oncology.
[21] S. Rosenberg,et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients , 2017, Annals of Surgical Oncology.
[22] A. Haydon,et al. Metastatic pathways in patients with cutaneous melanoma , 2017, Pigment cell & melanoma research.
[23] H. Minn,et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma* , 2016, Acta oncologica.
[24] J. Hansson,et al. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature , 2016, Clinical epidemiology.
[25] A. Francken,et al. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year , 2016, Annals of Surgical Oncology.
[26] D. O'Leary,et al. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy , 2016, Melanoma research.
[27] A. Hauschild,et al. Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study , 2015, The British journal of dermatology.
[28] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[29] J. Cormier,et al. Long-term follow-up for melanoma patients: is there any evidence of a benefit? , 2015, Surgical oncology clinics of North America.
[30] Yan Xing,et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review , 2012, Melanoma research.
[31] Andrew Hayen,et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Coit,et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Yeh,et al. Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging , 2009, Annals of Surgical Oncology.
[34] A. Bleyer,et al. Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program , 2004 .
[35] Claus Garbe,et al. The natural course of cutaneous melanoma , 2004, Journal of surgical oncology.
[36] C. O'brien,et al. Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy , 2004, Annals of Surgical Oncology.
[37] U. Chetty,et al. A rational approach to melanoma follow‐up in patients with primary cutaneous melanoma , 1999, The British journal of dermatology.
[38] S. Ariyan,et al. Data on First Recurrence after Treatment for Malignant Melanoma in a Large Patient Population , 1993, Plastic and reconstructive surgery.
[39] Samantha Barbour Mbbs,et al. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable? , 2014, Annals of Surgical Oncology.
[40] T. Johnson. Guidelines of care for the management of primary cutaneous melanoma. , 2013, Journal of the American Academy of Dermatology.
[41] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[42] F. Meier,et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma , 2002, The British journal of dermatology.
[43] U. Ringborg,et al. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. , 1999, Acta oncologica.